25 results about "Corneal cell" patented technology

The invention relates to eye drops containing exosomes and a preparation method and application thereof, and belongs to the technical field of eye drop preparation, the eye drops comprise exosome freeze-dried powder, the exosome freeze-dried powder is prepared from the exosomes obtained after mesenchymal stem cells are treated with TNF-alpha and IFN-alpha, and a herba houttuyniae extract, the eye drops provided by the invention can inhibit the phenotype of macrophage M1 and promote the M1 to be converted into the phenotype of M2; human corneal cell proliferation, migration and damage repair are promoted; mouse cornea injury repair is accelerated; the eye drops can be used for treating xerophthalmia, conjunctivitis and keratitis, and can also be used for preventing eye diseases and relieving asthenopia; the eye drops disclosed by the invention contain the exosome obtained after the mesenchymal stem cells are treated by the TNF-alpha and the IFN-alpha, so that the anti-inflammatory ability is stronger; the mesenchymal stem cell exosome and the herba houttuyniae extract are stored in a freeze-dried form, so that the activity is stable, and the storage time is long; in addition, the cordate houttuynia is cooperated with the exosome, so that the effect playing time can be prolonged, and the use frequency is reduced.

The invention provides a myopia grading method driven by coupling of mechanical and morphological characteristics of corneal cells, and belongs to the technical field of myopia eye disease diagnosis and occurrence and development mechanisms based on artificial intelligence. The surface topography, Young modulus, adhesive power and other mechanical characteristics of corneal cells of patients with low, medium and high myopia are measured, corneal cell surface topography images obtained by an atomic force microscope are used as a cytoskeleton quantitative analysis data set, and edge extraction, brightness detection and multi-scale image segmentation methods are utilized to determine the surface topography of the corneal cells of the patients with low, medium and high myopia. The overall cytoskeleton distribution characteristics are quantified through the cytoskeleton region average complexity and cytoskeleton region average similarity, the method does not depend on dyeing, the tissue structure of the cytoskeleton can be evaluated more comprehensively, the method is suitable for more diversified cytoskeleton structures including complex clusters, a myopia grading model is established, and the myopia grading efficiency is improved. And a more direct cellular-level experimental basis is provided for the research on the occurrence and development mechanism of myopia.

The ophthalmic composition according to the present invention contains: (A) 0.01-0.5 w / w% of a copolymer having structural units represented by formulae (1a)-(1c), the molar ratio of the structural units being a: b: c = 100: 10-400: 2-50, and the weight-average molecular weight being 5,000-2,000,000; (B) from 0.001 w / w% to 0.02 w / w% (inclusive) of benzalkonium chloride; and / or (C) from 0.001 w / w% to 0.05 w / w% (inclusive) of chlorhexidine gluconate. According to the present invention, it is possible to provide an ophthalmic composition that protects corneal cells while exhibiting sufficient storage efficacy.

The application discloses a kind of corneal near physiological biomechanics intelligent simulation method and device, it is related to biomechanics and biomechanics experimental device technical field, the present application includes mutually connected force load cavity, force loading component, sensor monitoring feedback component etc..The present application can realize to corneal repair material, corneal cell, corneal cell-material compound loading individual and compound flow shear force, static pressure, dynamic pressure, static tension and dynamic tension, gas-liquid dynamic culture is simultaneously carried out, and through pressure and flow sensor, the stress size of loading is monitored in real time, reach accurate intelligent comprehensive simulation cornea in body environment.The scheme provided by the present application can be used for the mechanical property detection of corneal tissue and material, obtains the material attribute under near physiological state;It can also be used for the mechanical loading of cell, to observe the cell behavior and functional change after near physiological mechanical loading.

Methods of treating eyes are described. The method may include administering an agent capable of disrupting corneal cell junctures to a corneal surface of the eye, the corneal surface comprising an intact epithelium and stroma; and administering riboflavin to the corneal surface after or simultaneously with the agent. The riboflavin may diffuse through the eye to penetrate the stroma within 10 minutes of administration of the riboflavin.

The present invention relates to the use of corneal cell-derived mitochondria for the prevention or treatment of corneal damage or corneal endothelial cell diseases. It has been confirmed that mitochondria isolated from corneal endothelial cells differentiated from induced pluripotent stem cells (iPSCs) of the present invention alleviate the inflammatory response of corneal endothelial cells in an inflammatory environment, restore the integrity and function of corneal endothelial cells, and, when delivered into heterologous primary corneal endothelial cells, suppress inflammatory responses, particularly inflammation caused by physical damage, and promote the regeneration of corneal endothelial cells. Therefore, mitochondria possessing such effects can overcome the tumorigenic limitations of conventional stem cell therapies, and due to their ease of production and minimal regulatory requirements, they offer excellent cost-effectiveness and broad applicability.

The application discloses a kind of living cornea confocal tomography microscope imaging systems, belong to ophthalmic imaging technical field.The objective of the present application includes successively: first mirror group, diaphragm, second mirror group and third mirror group from image side to object side, objective surface covers corneal cap;Mirror group meets the proportion relationship of design between each other.The micro objective lens proposed in the present application can perform high-resolution imaging on corneal cells of different layers, and the imaging quality is close to the diffraction limit, and the experimental results prove that, cooperating with corneal cap, the present application can clearly obtain high-resolution images of cells in different layers within the range of 0-572 μm, and the object field is large, so it is not necessary to repeatedly move the inspection equipment to adjust the shooting area during the inspection process;Working distance is long, compared with prior art, doctors can obtain more operating space, significantly reduce the operation difficulty of corneal imaging, and further improve the diagnosis efficiency.

The invention discloses a low-energy photocuring ophthalmic sealant and a preparation method and application thereof.The ophthalmic sealant is in-situ photocuring bi-crosslinking biological hydrogel, a functional complementary composite system is constructed through collaborative optimization, and the ophthalmic sealant mainly comprises methacrylated gelatin (GelMA), a cornea extracellular matrix component, glutamine transaminase and a photoinitiator. According to the invention, a double-network construction strategy combining low-energy photocuring and enzymatic crosslinking is adopted, and curing can be triggered under the extremely low optical power density not higher than 5 mW / cm, so that the clinical application bottlenecks of tissue damage caused by too high energy of a traditional photocuring material for eyes and insufficient mechanical property and stability of a single crosslinking system are overcome. The sealing agent has excellent tissue adhesion, mechanical stability and biocompatibility in a double-crosslinking hydrogel state, can realize minimally invasive sutureless repair of corneal defects, and effectively promotes functional regeneration of corneal tissues.

The invention provides a method for constructing a tissue engineered cornea based on human amniotic epithelial stem cells and application, and belongs to the technical field of biology. The method comprises the following steps: 1) culturing human amniotic epithelial stem cells in a corneal epithelial cell induced differentiation culture medium to obtain human corneal epithelial cell-like cells; culturing the human amniotic epithelial stem cells in a corneal stroma cell induced differentiation culture medium to obtain corneal stroma cells; and 2) respectively inoculating the human corneal epithelial cell-like cells and corneal stroma cells obtained in the step 1) on the surface and inside of an acellular corneal stroma scaffold, and co-culturing for 5 days to construct the tissue engineered cornea. According to the method, the two corneal cells derived from the human amniotic epithelial stem cells are simultaneously inoculated to the human decellularized corneal stroma for the first time, the tissue-engineered cornea is successfully constructed, in addition, the corneal cells obtained through differentiation can be inoculated to various types of biological materials such as hydrogel, and the tissue-engineered cornea is obtained. Wider application possibility is provided for developing various novel artificial cornea products.

The invention provides a hydrogel for corneal repair and a preparation method thereof, the hydrogel for corneal repair comprises the following raw materials by weight: 100 parts of thiolated hydroxyethyl chitosan; 20 to 40 parts of hyaluronic acid; and 10 to 20 parts of N-methyl-D-glucosamine. The hydrogel for corneal repair is used as a drug carrier, has good adhesiveness with cornea and good cell compatibility, can reduce inflammatory response caused by long-term contact with the cornea, and promotes regeneration and repair of corneal cells.

The invention discloses a non-invasive refraction treatment device and method, and the device comprises a hard cornea contact lens; the flexible circuit patch is connected with the rigid cornea contact lens, and the flexible circuit patch comprises an electrode structure; the generating device is used for electrifying the electrode structure in a wireless or wired manner, and an electric field is generated between the positive electrode and the negative electrode of the electrode structure and is used for generating a current path in a cornea and softening cornea tissues when the hard cornea contact lens is placed into an eye. The corneal shaping method has the following beneficial effects: 1, the whole shaping process only needs several minutes, so that the corneal shaping time is greatly shortened; and 2, the temperature change in the eyes of the wearer is detected and the discharge pulse width, voltage and discharge frequency of the pulse generation device are dynamically adjusted while programmed control and current release are carried out, so that corneal cell damage caused by temperature rise is avoided, the corneal shaping risk is reduced, and the safety is greatly improved.

The application provides a method for constructing a tissue-engineered cornea based on human amniotic epithelial stem cells and application thereof, and belongs to the technical field of biotechnology. The method comprises the following steps: 1) culturing human amniotic epithelial stem cells in a corneal epithelial cell induction and differentiation culture medium to obtain human corneal epithelial cell-like cells; culturing the human amniotic epithelial stem cells in a corneal stromal cell induction and differentiation culture medium to obtain corneal stromal cells; 2) inoculating the human corneal epithelial cell-like cells and the corneal stromal cells obtained in step 1) on the surface and inside of a decellularized corneal stromal scaffold respectively, and co-culturing for 5 days to construct a tissue-engineered cornea. The application successfully constructs a tissue-engineered cornea by inoculating two kinds of corneal cells derived from human amniotic epithelial stem cells on a human decellularized corneal stromal at the same time for the first time. In addition, the obtained corneal cells can be inoculated on various types of biomaterials such as hydrogels, thereby providing a wider application possibility for developing various types of artificial cornea products.

The invention discloses a bioengineering corneal cell culture solution for repairing corneal ulcer and a preparation process of the bioengineering corneal cell culture solution. According to the invention, the addition of various growth factors not only promotes the proliferation and differentiation of corneal cells, but also enhances the signal transduction between cells, thereby accelerating the repair process of corneal ulcer. The epidermal growth factor and the basic fibroblast growth factor mainly promote cell proliferation and migration and provide a new cell source for an ulcer surface; the transforming growth factor-beta regulates the synthesis and remodeling of an extracellular matrix, and is helpful for recovering the normal structure of the cornea; and the corneal cell growth factor specifically promotes the growth of corneal epithelial cells. Through the multi-factor synergistic effect, the ulcer repairing speed is increased, the repairing quality is improved, scar formation is reduced, and a clearer and healthier vision recovery effect is brought to a patient.

Methods are provided for the cell-based delivery of collagen VII for the treatment of Epidermolysis Bullosa and corneal erosion. The disclosure also provides a composition and a pharmaceutical composition comprises, comprise, or alternatively consist essentially of, or yet further consist of a keratinocyte sheet or a corneal cell sheet.

Methods are provided for the cell-based delivery of collagen VII for the treatment of Epidermolysis Bullosa and corneal erosion. The disclosure also provides a composition and a pharmaceutical composition comprises, comprise, or alternatively consist essentially of, or yet further consist of a keratinocyte sheet or a corneal cell sheet.

The present invention provides an artificial cornea stent and a preparation method thereof, belonging to the technical field of new material preparation; the preparation process includes the following steps: preparation of modified krill protein; preparation of polymethyl methacrylate microsphere template; modification of polyacrylic acid with modified krill protein; preparation of N-isopropylacrylamide monomer reaction solution; preparation of artificial cornea stent. In the present invention, the material composition of the double-network hydrogel has low cytotoxicity and immunogenicity, can reduce the irritation and rejection reaction to ocular tissues, is helpful for cell attachment and growth, and the interpenetrating double-network structure endows the stent with sufficient strength and toughness, enabling it to withstand the normal physiological pressure and movement of the eye, while maintaining the structural stability. The porous property is conducive to the exchange of nutrients and metabolic wastes, provides a good microenvironment for cell survival and function maintenance, and can also guide the migration, proliferation and differentiation of corneal cells, contributing to the repair and regeneration of damaged corneal tissues.

The present invention concerns an in vitro test for detecting the irritant potential of chemicals combining a corneal cell model with a selection of predictive and qualitative molecular markers to classify compounds into 3 categories, namely irreversible eye damage 21 days after application (category 1), reversible eye damage 21 days after application (category 2) and no irritation (no category). The inventors have thus demonstrated that the response following the action of an irritant substance occurs directly on an in vitro reconstructed corneal epithelium, and that the degree of irritation and the qualification of this irritation of a molecule may be determined by the use of specific biomarkers of eye irritation.

A microporous biocomposite that is suitable for surgical implantation in an avascular environment is provided. The microporous biocomposite includes (1) a polymer scaffold having a thickness less than about 100 μm and nodal structures that extend to at least one surface of the polymer scaffold and (2) a hydrophilic coating on the polymer scaffold. In some embodiments, the porous scaffold is a microporous biomaterial with nodal structures that extend from a first surface to a second surface of the microporous biomaterial. The hydrophilic coating may be a node and fibril coating. The microporous biocomposite allows for the integration and sustained viability of epithelial cells on the surface thereof as well as tissue integration and the internal colonization of the biomaterial with other cell types, such as keratocytes and fibroblasts. In at least one embodiment, the microporous biocomposite may be incorporated into an artificial corneal implant or in other avascular mesoplants.

The present invention relates to a corneal cell culture support comprising graphene and its uses. The graphene-containing support of the present invention is non-toxic to corneal cells, is optimized for the cell proliferation rate, adhesion rate, and survival rate of corneal cells, enhances the expression of corneal cell-specific genes, and can maintain an optimized corneal cell state through cytoskeletal remodeling and mitochondrial activation. Therefore, the corneal cell culture support has the effect of being utilized in cell therapies, implant materials in the field of regenerative medicine, and tissue engineering platforms.

Methods are provided for the cell-based delivery of collagen VII for the treatment of Epidermolysis Bullosa and corneal erosion. The disclosure also provides a composition and a pharmaceutical composition comprises, comprise, or alternatively consist essentially of, or yet further consist of a keratinocyte sheet or a corneal cell sheet.

The invention relates to a preparation process of a polydimethylsiloxane injection surface for releasing a cell sheet and application of the polydimethylsiloxane injection surface in corneal reconstruction. The abstract content is inspired by a smooth surface of a pitcher plant flesh opening to trap insects into a bag. A scientist introduces smooth liquid as an unbonded coating into the surface of a porous material to achieve the purposes of resisting pollution, preventing dust, preventing adhesion growth of marine invertebrate organisms and preventing rust, the silica gel culture dish is researched, developed and prepared by referring to related data to solve the problem of cell sheet adhesion removal by applying the technology, and after modification, film coating, inoculated culture and adhesion removal treatment, the cell sheet adhesion removal effect is improved. After many times of failures, the corneal epithelium cell sheet is removed, the cell sheet is further identified to be a cell sheet with high survival rate and regeneration capacity, and animal corneal cell sheet transplantation experiments confirm that the transplanted cell sheet can be quickly decocted with the damaged corneal epithelium, so that the corneal epithelium cell sheet can be quickly adhered to the damaged corneal epithelium, and the corneal epithelium cell sheet can be quickly adhered to the damaged corneal epithelium. And a P63 labeled protein with regeneration characteristics is observed to exist in a cornea layer through tissue slice staining.

The embodiment of the invention provides an application of a proton pump inhibitor or a derivative thereof, or a compound thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof in preparation of anti-xerophthalmia drugs. The proton pump inhibitor is prepared from any one or a combination of at least two of omeprazole, lansoprazole, pantoprazole, rabeprazole, reminoprazole, esomeprazole or tenatoprazole. According to the application, the proton pump inhibitor is loaded on the self-assembled nucleic acid, so that the composite material has efficient corneal cell membrane penetrating capacity, and can remarkably inhibit expression of inflammatory factors and improve the ocular surface inflammation microenvironment; in addition, the compound also has relatively good biological safety, shows an excellent treatment effect on in-vivo and in-vitro xerophthalmia models, and provides a new choice for clinical xerophthalmia treatment.

Methods are provided for the cell-based delivery of collagen VII for the treatment of Epidermolysis Bullosa and corneal erosion. The disclosure also provides a composition and a pharmaceutical composition comprises, comprise, or alternatively consist essentially of, or yet further consist of a keratinocyte sheet or a corneal cell sheet.

The invention discloses a cornea tissue preservation and drug testing device and a cornea tissue preservation method. The preservation and drug testing device comprises a container, a hydrogel bracket fixed at the bottom of the container, a collagen barrier membrane covering the hydrogel bracket and a culture solution contained in the container and used for maintaining the physiological state of cornea tissue. The surface, used for bearing cornea tissues, of the hydrogel bracket is a convex spherical surface, and the curvature range of the convex spherical surface is 30-65D; the collagen barrier membrane comprises a collagen membrane used for covering cornea tissue and a hollow circular ring used for fixing the collagen membrane. When the preservation and drug testing device is used for preserving the cornea tissue, the existence state and environment of the cornea tissue in a human body can be simulated, metabolic waste of cells in the cornea tissue can be effectively exchanged, and the preservation and drug testing device plays a very positive role in maintaining the shape, thickness and transparency of the cornea cells.